Unlock stock picks and a broker-level newsfeed that powers Wall Street.

LSE - Delayed Quote GBp

Oxford BioDynamics Plc (OBD.L)

Compare
0.4690
+0.0190
+(4.22%)
As of 11:48:23 AM GMT+1. Market Open.
Currency in GBP All numbers in thousands
Download
Breakdown
TTM
9/30/2024
9/30/2023
9/30/2022
9/30/2021
Total Revenue
636
636
510
154
341
Cost of Revenue
347
347
244
38
--
Gross Profit
289
289
266
116
341
Operating Expense
12,287
12,287
10,434
8,717
7,853
Operating Income
-11,998
-11,998
-10,168
-8,601
-7,512
Net Non Operating Interest Income Expense
-113
-113
-141
-184
-83
Pretax Income
-11,956
-11,956
-11,411
-7,567
-7,629
Tax Provision
-389
-389
-585
-857
-947
Net Income Common Stockholders
-11,567
-11,567
-10,826
-6,710
-6,682
Diluted NI Available to Com Stockholders
-11,567
-11,567
-10,826
-6,710
-6,682
Basic EPS
-0.04
-0.04
-0.07
-0.07
-0.07
Diluted EPS
-0.04
-0.04
-0.07
-0.07
-0.07
Basic Average Shares
255,728.8890
255,728.8890
147,481.5660
99,702.2570
92,559.7710
Diluted Average Shares
255,728.8890
255,728.8890
147,481.5660
99,702.2570
92,559.7710
Total Operating Income as Reported
-12,894
-12,894
-10,168
-8,601
-7,512
Total Expenses
12,634
12,634
10,678
8,755
7,853
Net Income from Continuing & Discontinued Operation
-11,567
-11,567
-10,826
-6,710
-6,682
Normalized Income
-10,700.1522
-10,700.1522
-10,933.2069
-6,710
-6,682
Interest Income
112
112
72
11
31
Interest Expense
225
225
213
195
114
Net Interest Income
-113
-113
-141
-184
-83
EBIT
-11,731
-11,731
-11,198
-7,372
-7,515
EBITDA
-10,265
-10,265
-9,841
-6,159
-6,427
Reconciled Cost of Revenue
347
347
244
38
--
Reconciled Depreciation
1,466
1,466
1,357
1,213
1,088
Net Income from Continuing Operation Net Minority Interest
-11,567
-11,567
-10,826
-6,710
-6,682
Total Unusual Items Excluding Goodwill
-896
-896
113
--
--
Total Unusual Items
-896
-896
113
--
--
Normalized EBITDA
-9,369
-9,369
-9,954
-6,159
-6,427
Tax Rate for Calcs
0
0
0.0001
0.0001
0.0001
Tax Effect of Unusual Items
-29.1522
-29.1522
5.7931
--
--
9/30/2021 - 12/6/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AREC.L Arecor Therapeutics plc
38.50
+1.32%
 
ARDX.MX Ardelyx, Inc.
105.50
0.00%
 
HQ1.MU Oruka Therapeutics Inc. R
7.35
+4.26%
 
P0F.F Egetis Therapeutics AB (publ)
0.2910
-1.52%
 
MVR0.BE Medivir AB
0.1406
+42.16%
 
RPD.MU Royalty Pharma plc
28.20
0.00%
 
ICY.HA Incyte Corp
50.74
-2.69%
 
7PO.F Poxel S.A.
0.4245
-5.88%
 
DBV.F DBV Technologies S.A.
1.2300
-0.65%
 
PROT Proteonomix, Inc.
0.0000
0.00%